CARL ZEISS MEDITEC AG - BR (AFX.DE) Fundamental Analysis & Valuation

FRA:AFX • DE0005313704

Current stock price

24.84 EUR
-0.06 (-0.24%)
Last:

This AFX.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. AFX.DE Profitability Analysis

1.1 Basic Checks

  • AFX had positive earnings in the past year.
  • In the past year AFX had a positive cash flow from operations.
  • Each year in the past 5 years AFX has been profitable.
  • AFX had a positive operating cash flow in each of the past 5 years.
AFX.DE Yearly Net Income VS EBIT VS OCF VS FCFAFX.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

1.2 Ratios

  • AFX's Return On Assets of 4.15% is fine compared to the rest of the industry. AFX outperforms 62.30% of its industry peers.
  • The Return On Equity of AFX (6.67%) is comparable to the rest of the industry.
  • AFX has a Return On Invested Capital (5.79%) which is comparable to the rest of the industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for AFX is below the industry average of 10.18%.
Industry RankSector Rank
ROA 4.15%
ROE 6.67%
ROIC 5.79%
ROA(3y)6.33%
ROA(5y)7.85%
ROE(3y)9.62%
ROE(5y)11.54%
ROIC(3y)7.11%
ROIC(5y)9.66%
AFX.DE Yearly ROA, ROE, ROICAFX.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10

1.3 Margins

  • AFX has a Profit Margin (6.34%) which is comparable to the rest of the industry.
  • In the last couple of years the Profit Margin of AFX has declined.
  • AFX's Operating Margin of 10.03% is in line compared to the rest of the industry. AFX outperforms 47.54% of its industry peers.
  • In the last couple of years the Operating Margin of AFX has declined.
  • AFX has a worse Gross Margin (52.76%) than 60.66% of its industry peers.
  • In the last couple of years the Gross Margin of AFX has remained more or less at the same level.
Industry RankSector Rank
OM 10.03%
PM (TTM) 6.34%
GM 52.76%
OM growth 3Y-21.67%
OM growth 5Y-5.49%
PM growth 3Y-25.69%
PM growth 5Y-7.11%
GM growth 3Y-3.8%
GM growth 5Y-1.12%
AFX.DE Yearly Profit, Operating, Gross MarginsAFX.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40 50

6

2. AFX.DE Health Analysis

2.1 Basic Checks

  • AFX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • AFX has about the same amout of shares outstanding than it did 1 year ago.
  • AFX has less shares outstanding than it did 5 years ago.
  • AFX has a better debt/assets ratio than last year.
AFX.DE Yearly Shares OutstandingAFX.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
AFX.DE Yearly Total Debt VS Total AssetsAFX.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.2 Solvency

  • An Altman-Z score of 2.81 indicates that AFX is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • AFX has a Altman-Z score of 2.81. This is comparable to the rest of the industry: AFX outperforms 57.38% of its industry peers.
  • AFX has a debt to FCF ratio of 4.41. This is a neutral value as AFX would need 4.41 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 4.41, AFX is in the better half of the industry, outperforming 60.66% of the companies in the same industry.
  • AFX has a Debt/Equity ratio of 0.27. This is a healthy value indicating a solid balance between debt and equity.
  • AFX has a Debt to Equity ratio (0.27) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF 4.41
Altman-Z 2.81
ROIC/WACC0.88
WACC6.56%
AFX.DE Yearly LT Debt VS Equity VS FCFAFX.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B 2B

2.3 Liquidity

  • AFX has a Current Ratio of 2.35. This indicates that AFX is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Current ratio value of 2.35, AFX is doing good in the industry, outperforming 67.21% of the companies in the same industry.
  • A Quick Ratio of 1.44 indicates that AFX should not have too much problems paying its short term obligations.
  • AFX has a better Quick ratio (1.44) than 67.21% of its industry peers.
Industry RankSector Rank
Current Ratio 2.35
Quick Ratio 1.44
AFX.DE Yearly Current Assets VS Current LiabilitesAFX.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

4

3. AFX.DE Growth Analysis

3.1 Past

  • The earnings per share for AFX have decreased strongly by -17.51% in the last year.
  • AFX shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 3.28% yearly.
  • AFX shows a small growth in Revenue. In the last year, the Revenue has grown by 5.89%.
  • Measured over the past years, AFX shows a quite strong growth in Revenue. The Revenue has been growing by 10.78% on average per year.
EPS 1Y (TTM)-17.51%
EPS 3Y-21.2%
EPS 5Y3.28%
EPS Q2Q%-83.33%
Revenue 1Y (TTM)5.89%
Revenue growth 3Y5.39%
Revenue growth 5Y10.78%
Sales Q2Q%-4.79%

3.2 Future

  • AFX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.94% yearly.
  • The Revenue is expected to grow by 5.17% on average over the next years.
EPS Next Y1.24%
EPS Next 2Y12.96%
EPS Next 3Y14.01%
EPS Next 5Y14.94%
Revenue Next Year2.21%
Revenue Next 2Y3.76%
Revenue Next 3Y4.34%
Revenue Next 5Y5.17%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
AFX.DE Yearly Revenue VS EstimatesAFX.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B 2B 2.5B
AFX.DE Yearly EPS VS EstimatesAFX.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1 2 3

6

4. AFX.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • AFX is valuated rather expensively with a Price/Earnings ratio of 17.01.
  • 81.97% of the companies in the same industry are more expensive than AFX, based on the Price/Earnings ratio.
  • AFX is valuated rather cheaply when we compare the Price/Earnings ratio to 25.60, which is the current average of the S&P500 Index.
  • A Price/Forward Earnings ratio of 12.09 indicates a correct valuation of AFX.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of AFX indicates a rather cheap valuation: AFX is cheaper than 83.61% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 22.84, AFX is valued a bit cheaper.
Industry RankSector Rank
PE 17.01
Fwd PE 12.09
AFX.DE Price Earnings VS Forward Price EarningsAFX.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • AFX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. AFX is cheaper than 88.52% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, AFX is valued cheaply inside the industry as 85.25% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 16.67
EV/EBITDA 7.82
AFX.DE Per share dataAFX.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • A more expensive valuation may be justified as AFX's earnings are expected to grow with 14.01% in the coming years.
PEG (NY)13.68
PEG (5Y)5.19
EPS Next 2Y12.96%
EPS Next 3Y14.01%

4

5. AFX.DE Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 2.20%, AFX has a reasonable but not impressive dividend return.
  • The stock price of AFX dropped by -37.30% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
  • Compared to an average industry Dividend Yield of 1.14, AFX pays a bit more dividend than its industry peers.
  • AFX's Dividend Yield is comparable with the S&P500 average which is at 1.88.
Industry RankSector Rank
Dividend Yield 2.2%

5.2 History

  • The dividend of AFX decreases each year by -1.59%.
Dividend Growth(5Y)-1.59%
Div Incr Years1
Div Non Decr Years4
AFX.DE Yearly Dividends per shareAFX.DE Yearly Dividends per shareYearly Dividends per share 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6 0.8 1

5.3 Sustainability

  • 37.19% of the earnings are spent on dividend by AFX. This is a low number and sustainable payout ratio.
DP37.19%
EPS Next 2Y12.96%
EPS Next 3Y14.01%
AFX.DE Yearly Income VS Free CF VS DividendAFX.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M 200M 250M
AFX.DE Dividend Payout.AFX.DE Dividend Payout, showing the Payout Ratio.AFX.DE Dividend Payout.PayoutRetained Earnings

AFX.DE Fundamentals: All Metrics, Ratios and Statistics

CARL ZEISS MEDITEC AG - BR

FRA:AFX (4/2/2026, 7:00:00 PM)

24.84

-0.06 (-0.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-12
Earnings (Next)05-11
Inst Owners24.4%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.22B
Revenue(TTM)2.20B
Net Income(TTM)141.22M
Analysts66.09
Price Target36 (44.93%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.2%
Yearly Dividend0.6
Dividend Growth(5Y)-1.59%
DP37.19%
Div Incr Years1
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-21.46%
Min EPS beat(2)-33.88%
Max EPS beat(2)-9.05%
EPS beat(4)1
Avg EPS beat(4)-16.59%
Min EPS beat(4)-36.67%
Max EPS beat(4)13.25%
EPS beat(8)4
Avg EPS beat(8)-3.62%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.89%
Min Revenue beat(2)-1.14%
Max Revenue beat(2)2.92%
Revenue beat(4)3
Avg Revenue beat(4)1.59%
Min Revenue beat(4)-1.14%
Max Revenue beat(4)3.76%
Revenue beat(8)5
Avg Revenue beat(8)-0.32%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.46%
PT rev (3m)-29.62%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-30.35%
EPS NY rev (1m)-15.87%
EPS NY rev (3m)-18.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.03%
Revenue NY rev (1m)-0.48%
Revenue NY rev (3m)-1.94%
Valuation
Industry RankSector Rank
PE 17.01
Fwd PE 12.09
P/S 1
P/FCF 16.67
P/OCF 10.59
P/B 1.05
P/tB 4.59
EV/EBITDA 7.82
EPS(TTM)1.46
EY5.88%
EPS(NY)2.05
Fwd EY8.27%
FCF(TTM)1.49
FCFY6%
OCF(TTM)2.35
OCFY9.45%
SpS24.91
BVpS23.66
TBVpS5.41
PEG (NY)13.68
PEG (5Y)5.19
Graham Number27.88
Profitability
Industry RankSector Rank
ROA 4.15%
ROE 6.67%
ROCE 7.81%
ROIC 5.79%
ROICexc 5.89%
ROICexgc 14.08%
OM 10.03%
PM (TTM) 6.34%
GM 52.76%
FCFM 5.98%
ROA(3y)6.33%
ROA(5y)7.85%
ROE(3y)9.62%
ROE(5y)11.54%
ROIC(3y)7.11%
ROIC(5y)9.66%
ROICexc(3y)7.22%
ROICexc(5y)9.75%
ROICexgc(3y)13.97%
ROICexgc(5y)15.82%
ROCE(3y)9.59%
ROCE(5y)13.04%
ROICexgc growth 3Y-8.4%
ROICexgc growth 5Y5.55%
ROICexc growth 3Y-23.03%
ROICexc growth 5Y-5.34%
OM growth 3Y-21.67%
OM growth 5Y-5.49%
PM growth 3Y-25.69%
PM growth 5Y-7.11%
GM growth 3Y-3.8%
GM growth 5Y-1.12%
F-Score6
Asset Turnover0.65
Health
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF 4.41
Debt/EBITDA 1.61
Cap/Depr 60.61%
Cap/Sales 3.44%
Interest Coverage 10.38
Cash Conversion 60%
Profit Quality 94.37%
Current Ratio 2.35
Quick Ratio 1.44
Altman-Z 2.81
F-Score6
WACC6.56%
ROIC/WACC0.88
Cap/Depr(3y)109.66%
Cap/Depr(5y)110.76%
Cap/Sales(3y)5.42%
Cap/Sales(5y)4.92%
Profit Quality(3y)64.92%
Profit Quality(5y)71.29%
High Growth Momentum
Growth
EPS 1Y (TTM)-17.51%
EPS 3Y-21.2%
EPS 5Y3.28%
EPS Q2Q%-83.33%
EPS Next Y1.24%
EPS Next 2Y12.96%
EPS Next 3Y14.01%
EPS Next 5Y14.94%
Revenue 1Y (TTM)5.89%
Revenue growth 3Y5.39%
Revenue growth 5Y10.78%
Sales Q2Q%-4.79%
Revenue Next Year2.21%
Revenue Next 2Y3.76%
Revenue Next 3Y4.34%
Revenue Next 5Y5.17%
EBIT growth 1Y14.86%
EBIT growth 3Y-17.44%
EBIT growth 5Y4.69%
EBIT Next Year51.32%
EBIT Next 3Y23.17%
EBIT Next 5Y16.25%
FCF growth 1Y40.11%
FCF growth 3Y7.85%
FCF growth 5Y-0.04%
OCF growth 1Y-15.15%
OCF growth 3Y3.7%
OCF growth 5Y3.29%

CARL ZEISS MEDITEC AG - BR / AFX.DE Fundamental Analysis FAQ

What is the fundamental rating for AFX stock?

ChartMill assigns a fundamental rating of 5 / 10 to AFX.DE.


What is the valuation status for AFX stock?

ChartMill assigns a valuation rating of 6 / 10 to CARL ZEISS MEDITEC AG - BR (AFX.DE). This can be considered as Fairly Valued.


What is the profitability of AFX stock?

CARL ZEISS MEDITEC AG - BR (AFX.DE) has a profitability rating of 4 / 10.


What is the financial health of CARL ZEISS MEDITEC AG - BR (AFX.DE) stock?

The financial health rating of CARL ZEISS MEDITEC AG - BR (AFX.DE) is 6 / 10.


Can you provide the dividend sustainability for AFX stock?

The dividend rating of CARL ZEISS MEDITEC AG - BR (AFX.DE) is 4 / 10 and the dividend payout ratio is 37.19%.